Welcome to our dedicated page for OSR Holdings news (Ticker: OSRH), a resource for investors and traders seeking the latest updates and insights on OSR Holdings stock.
OSR Holdings, Inc. (NASDAQ: OSRH) generates news across multiple areas of healthcare and biotechnology, reflecting its role as a global healthcare holding company focused on immuno-oncology, regenerative biologics, and medical device technologies. The company’s news flow often centers on developments at its key subsidiaries, strategic licensing discussions, clinical data updates, and corporate finance activities.
One major stream of OSR Holdings news relates to Vaximm AG, its Swiss-German immuno-oncology subsidiary. Press releases have detailed Vaximm’s proprietary orally administered T-cell vaccination platform, the clinical progress of lead candidate VXM01 targeting VEGFR-2, and negotiations with BCM Europe AG and affiliated investment vehicles for potential global exclusive licensing arrangements. Updates have covered non-binding and binding term sheets, proposed upfront and milestone payment structures, royalty pass-through mechanisms, and plans to obtain independent fairness opinions, providing insight into how OSR Holdings seeks to unlock value from its immunotherapy assets.
Another important category of news involves Woori IO Co., Ltd., a South Korea-based medical-device company focused on noninvasive glucose monitoring. OSR Holdings has issued releases on the signing and approval of a definitive share exchange agreement under which Woori IO becomes a wholly owned subsidiary of its Korean affiliate, as well as on Woori IO’s collaborations with Samsung Electronics on proof-of-concept studies. News items have also summarized pilot study results for the Glucheck blood glucose measurement system conducted with Korea University Guro Hospital, highlighting accuracy, precision, and ISO 15197:2013 compliance.
Investors following OSRH news will also see announcements about virtual investor events, conference presentations, equity financing arrangements, and Nasdaq listing matters, including notices regarding minimum bid price compliance. This dedicated news page allows readers to track OSR Holdings’ evolving portfolio, licensing initiatives, clinical milestones, and capital markets updates in one place, with new items added as the company furnishes press releases and related SEC communications.
OSR Holdings (NASDAQ: OSRH) said subsidiary Woori IO signed a mutual NDA with Sinopharm on March 19, 2026 to share confidential information about Woori IO's noninvasive NIR continuous glucose monitoring technology.
The agreement enables evaluation of regulatory, clinical, and commercial pathways in China, notes Sinopharm's reported 2024 revenue of about USD 81 billion, and cites China market size (>140 million people with diabetes) and a projected device market >$12 billion by 2032. Discussions remain preliminary while Woori IO pursues potential global multicenter trials and other partner engagements.
OSR Holdings (NASDAQ:OSRH) announced that subsidiary Woori IO signed a mutual NDA with Sinopharm on March 19, 2026 to exchange confidential information about Woori IO's noninvasive near-infrared (NIR) glucose monitoring technology.
The NDA enables evaluation of regulatory, clinical, and commercial pathways in China. Sinopharm reported 2024 revenue of approximately USD 81 billion. China has over 140 million people with diabetes and the device market could exceed $12 billion by 2032, highlighting potential commercial opportunity amid early-stage discussions.
OSR Holdings (NASDAQ:OSRH) received a 180-calendar-day Nasdaq extension to regain compliance with the $1.00 minimum bid price rule, extending the cure period to August 31, 2026. Trading of common stock remains uninterrupted under ticker OSRH.
The company reiterated strategic priorities: a potential VXM01 licensing transaction with USD 30 million upfront plus up to USD 815 million in milestones, and a medical device platform merger consolidating RMC and Woori IO.
OSR Holdings (OSRH) addressed Nasdaq minimum-bid timing and reaffirmed portfolio progress on February 2, 2026. Vaximm has a binding term sheet with BCM Europe proposing up to USD 815 million in milestones and USD 30 million upfront (USD 15M cash, USD 15M digital assets).
Separately, management is pursuing a potential merger of device subsidiaries RMC and Woori IO, enabled by recent FDA clarity that supports a dual-track commercialization strategy and growing inbound distributor interest.
OSR Holdings (NASDAQ:OSRH) completed the acquisition of Woori IO, effective January 26, 2026, making Woori IO a consolidated subsidiary and strengthening OSRH's noninvasive glucose monitoring and wearable health capabilities.
Legacy shareholders of Woori IO agreed to a three-year equity alignment to exchange OSR Holdings Co., Ltd. (OSRK) interests into NASDAQ-listed OSRH common stock only at a USD $10.00 per share reference price, intended to limit near-term dilution. OSRH also initiated a strategic review to potentially combine its medical device subsidiaries, Woori IO and RMC, to form an integrated medical technology and distribution company and evaluate a possible standalone IPO in Korea, subject to market, regulatory, and board approvals.
Woori IO (OSR Holdings, ticker OSRH) said the FDA clarified that consumer wearable products giving non-medical, wellness-oriented health insights—if properly labeled and marketed—generally fall outside medical-device pre-market review. Woori IO plans a two-phase commercialization: Phase 1 consumer-grade wellness wearables to accelerate time-to-market and gather real-world data; Phase 2 medical-grade CGM solutions pursued through appropriate regulatory pathways. The company cited collaboration plans with Samsung-related smartwatch platforms and said OSR Holdings expects to complete a previously announced share exchange with Woori IO on January 26, 2026.
Vaximm, a subsidiary of OSR Holdings (NYSE:OSRH), appointed Sébastien Wieckowski, PhD as Chief Scientific Officer on Jan 16, 2026. The company said his multidisciplinary background in immunology and advanced data science will lead strategic enhancements to the oral T‑cell VXM platform and support advancing the lead candidate VXM01 into later clinical stages while pursuing new targets. The appointment is positioned to strengthen R&D, platform reproducibility, and data‑driven discovery for oncology and non‑oncology programs.
OSR Holdings (NASDAQ: OSRH) said Vaximm, its Swiss subsidiary, received a binding term sheet from BCM Europe for a proposed global exclusive license of VXM01. Key financial terms include a $30 million upfront payment (50% cash, 50% digital assets) and up to $815 million in aggregate milestone payments weighted toward clinical and development achievements. The Fund proposed as licensee would pass through future sublicense royalties to Vaximm subject to reconciliation. Vaximm's board will seek an independent fairness opinion and targets a definitive agreement by end of May 2026, subject to customary conditions and approvals.
OSR Holdings (NASDAQ: OSRH) announced that Woori IO shareholders approved a share exchange at an Extraordinary General Meeting on Dec 19, 2025, which will make Woori IO a wholly-owned subsidiary of OSRK upon completion.
Woori IO is running a Samsung-supported PoC study in Korea aimed at Korean regulatory approval for its noninvasive blood glucose monitoring platform, and has received an invitation from a leading California research university to collaborate on a U.S. FDA clinical trial to support U.S. market development.
OSR Holdings (NASDAQ: OSRH) subsidiary Vaximm AG updated a non-binding term sheet with BCM Europe AG to shorten the exclusivity period from six months to three months, with the parties aiming to finalize a definitive exclusive global licensing agreement for VXM01 within that three-month window ending February 2026. The contemplated financial terms remain unchanged: a $20 million upfront payment, up to $815 million in clinical, regulatory, and commercial milestone payments, and a pass-through of commercial royalties via a defined delta-recovery mechanism. Vaximm retains IP ownership of VXM01 until a definitive license is executed. The term sheet also preserves an optional blockchain-based royalty participation mechanism using TAC tokens.